Jessica Rove
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 7 | 2024 | 749 | 2.460 |
Why?
| | Cardiac Surgical Procedures | 5 | 2024 | 531 | 2.200 |
Why?
| | Tissue and Organ Procurement | 6 | 2024 | 314 | 1.530 |
Why?
| | Extracorporeal Membrane Oxygenation | 5 | 2023 | 292 | 1.210 |
Why?
| | Thoracic Surgery | 2 | 2024 | 133 | 0.790 |
Why?
| | Educational Personnel | 1 | 2022 | 12 | 0.790 |
Why?
| | Lidocaine | 1 | 2022 | 42 | 0.780 |
Why?
| | Gelatin | 1 | 2022 | 50 | 0.770 |
Why?
| | Surgeons | 2 | 2024 | 298 | 0.770 |
Why?
| | Heart Valve Prosthesis | 1 | 2023 | 116 | 0.740 |
Why?
| | Mitral Valve Insufficiency | 1 | 2022 | 69 | 0.740 |
Why?
| | Vascular Grafting | 1 | 2020 | 13 | 0.690 |
Why?
| | General Surgery | 1 | 2022 | 170 | 0.670 |
Why?
| | Phospholipases A2, Secretory | 4 | 2019 | 12 | 0.650 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2022 | 182 | 0.640 |
Why?
| | Echocardiography | 1 | 2022 | 659 | 0.620 |
Why?
| | Perfusion | 5 | 2024 | 212 | 0.610 |
Why?
| | Esophageal Neoplasms | 3 | 2017 | 324 | 0.560 |
Why?
| | Stomach Diseases | 1 | 2017 | 20 | 0.540 |
Why?
| | Organ Preservation | 4 | 2024 | 102 | 0.520 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 154 | 0.520 |
Why?
| | Esophagectomy | 1 | 2017 | 131 | 0.490 |
Why?
| | Deglutition Disorders | 1 | 2017 | 143 | 0.470 |
Why?
| | Enzyme Inhibitors | 4 | 2013 | 845 | 0.470 |
Why?
| | Cognition | 1 | 2023 | 1192 | 0.460 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 703 | 0.460 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 854 | 0.460 |
Why?
| | Reoperation | 1 | 2017 | 569 | 0.450 |
Why?
| | Internship and Residency | 2 | 2020 | 1131 | 0.430 |
Why?
| | Group II Phospholipases A2 | 2 | 2012 | 9 | 0.400 |
Why?
| | Humans | 43 | 2024 | 137514 | 0.390 |
Why?
| | Lung Neoplasms | 5 | 2019 | 2494 | 0.370 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2113 | 0.360 |
Why?
| | Quality of Life | 1 | 2023 | 2870 | 0.350 |
Why?
| | Retrospective Studies | 12 | 2024 | 15628 | 0.350 |
Why?
| | Bronchiectasis | 2 | 2012 | 111 | 0.330 |
Why?
| | Pneumonectomy | 2 | 2012 | 154 | 0.320 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2012 | 1079 | 0.320 |
Why?
| | Postoperative Complications | 2 | 2017 | 2641 | 0.310 |
Why?
| | Heart | 2 | 2023 | 660 | 0.310 |
Why?
| | Tissue Donors | 4 | 2024 | 417 | 0.300 |
Why?
| | NF-kappa B | 5 | 2012 | 694 | 0.280 |
Why?
| | Apoptosis | 4 | 2013 | 2557 | 0.270 |
Why?
| | Lung Transplantation | 2 | 2024 | 309 | 0.260 |
Why?
| | United States | 7 | 2024 | 14696 | 0.260 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 360 | 0.260 |
Why?
| | Osteogenesis | 2 | 2012 | 187 | 0.260 |
Why?
| | Brain Death | 2 | 2024 | 46 | 0.260 |
Why?
| | Thoracic Surgical Procedures | 2 | 2024 | 73 | 0.250 |
Why?
| | Adult | 13 | 2024 | 37821 | 0.250 |
Why?
| | Intercellular Adhesion Molecule-1 | 3 | 2019 | 139 | 0.240 |
Why?
| | Aortic Valve Stenosis | 2 | 2012 | 229 | 0.240 |
Why?
| | Aortic Valve | 2 | 2012 | 352 | 0.230 |
Why?
| | Adenocarcinoma | 3 | 2013 | 937 | 0.230 |
Why?
| | Cell Proliferation | 3 | 2013 | 2482 | 0.230 |
Why?
| | Treatment Outcome | 7 | 2022 | 10821 | 0.220 |
Why?
| | Consensus | 2 | 2024 | 685 | 0.220 |
Why?
| | RNA Interference | 2 | 2012 | 464 | 0.220 |
Why?
| | Organ Preservation Solutions | 1 | 2023 | 46 | 0.210 |
Why?
| | Tissue and Organ Harvesting | 1 | 2024 | 71 | 0.210 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 30 | 0.210 |
Why?
| | Time Factors | 6 | 2024 | 6817 | 0.200 |
Why?
| | Physicians, Women | 1 | 2024 | 83 | 0.200 |
Why?
| | Biglycan | 1 | 2012 | 3 | 0.200 |
Why?
| | Coronary Artery Bypass | 2 | 2024 | 238 | 0.200 |
Why?
| | Travel | 1 | 2023 | 130 | 0.200 |
Why?
| | American Heart Association | 1 | 2024 | 306 | 0.200 |
Why?
| | Hernia, Inguinal | 1 | 2012 | 35 | 0.190 |
Why?
| | Herniorrhaphy | 1 | 2012 | 60 | 0.190 |
Why?
| | Echocardiography, Transesophageal | 1 | 2022 | 101 | 0.190 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 308 | 0.190 |
Why?
| | Jugular Veins | 1 | 2012 | 42 | 0.190 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 117 | 0.190 |
Why?
| | Hypothermia, Induced | 1 | 2022 | 79 | 0.190 |
Why?
| | Spinal Cord Ischemia | 1 | 2022 | 56 | 0.180 |
Why?
| | Technology Transfer | 1 | 2021 | 10 | 0.180 |
Why?
| | ras Proteins | 1 | 2012 | 151 | 0.180 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 329 | 0.180 |
Why?
| | Mitral Valve | 1 | 2022 | 89 | 0.180 |
Why?
| | Periodicals as Topic | 1 | 2024 | 211 | 0.180 |
Why?
| | Death | 1 | 2022 | 119 | 0.180 |
Why?
| | Pulmonary Valve Insufficiency | 1 | 2012 | 43 | 0.180 |
Why?
| | Thoracotomy | 2 | 2017 | 75 | 0.180 |
Why?
| | Computed Tomography Angiography | 1 | 2022 | 124 | 0.180 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2011 | 43 | 0.170 |
Why?
| | Graft Survival | 1 | 2023 | 540 | 0.170 |
Why?
| | Bronchi | 1 | 2012 | 261 | 0.170 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2022 | 131 | 0.170 |
Why?
| | Genetic Therapy | 1 | 2012 | 296 | 0.170 |
Why?
| | Calcinosis | 1 | 2012 | 235 | 0.170 |
Why?
| | Coronary Circulation | 1 | 2020 | 141 | 0.170 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 63 | 0.170 |
Why?
| | Seizures | 1 | 2023 | 431 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 236 | 0.160 |
Why?
| | Pain, Postoperative | 1 | 2022 | 272 | 0.160 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2022 | 202 | 0.160 |
Why?
| | Phosphorylation | 5 | 2013 | 1762 | 0.160 |
Why?
| | Blotting, Western | 5 | 2013 | 1227 | 0.160 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2021 | 130 | 0.160 |
Why?
| | Graft Rejection | 1 | 2023 | 623 | 0.160 |
Why?
| | Blood Flow Velocity | 1 | 2020 | 412 | 0.150 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 646 | 0.150 |
Why?
| | Heart Arrest | 1 | 2022 | 339 | 0.150 |
Why?
| | Dinoprostone | 1 | 2019 | 191 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2013 | 153 | 0.140 |
Why?
| | Phylogeny | 1 | 2022 | 898 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1465 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 186 | 0.140 |
Why?
| | Health Personnel | 1 | 2024 | 699 | 0.140 |
Why?
| | Mental Health | 1 | 2024 | 724 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 316 | 0.140 |
Why?
| | Cell Movement | 1 | 2012 | 972 | 0.140 |
Why?
| | Gastric Emptying | 1 | 2017 | 38 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 683 | 0.130 |
Why?
| | Critical Illness | 1 | 2023 | 809 | 0.130 |
Why?
| | Laparotomy | 1 | 2017 | 109 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2145 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 948 | 0.130 |
Why?
| | Cell Line, Tumor | 5 | 2012 | 3420 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 974 | 0.120 |
Why?
| | Hospital Mortality | 1 | 2020 | 902 | 0.120 |
Why?
| | Anxiety | 1 | 2023 | 1041 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 433 | 0.120 |
Why?
| | Hydrogels | 1 | 2022 | 675 | 0.120 |
Why?
| | Aged | 8 | 2024 | 23798 | 0.120 |
Why?
| | Asphyxia | 1 | 2014 | 20 | 0.110 |
Why?
| | Heart Defects, Congenital | 1 | 2012 | 832 | 0.110 |
Why?
| | Registries | 1 | 2021 | 2021 | 0.100 |
Why?
| | Clinical Competence | 1 | 2020 | 1093 | 0.100 |
Why?
| | Middle Aged | 8 | 2024 | 33355 | 0.100 |
Why?
| | Veterans | 1 | 2024 | 1461 | 0.100 |
Why?
| | Thoracoscopy | 2 | 2012 | 56 | 0.090 |
Why?
| | Radiation Injuries | 1 | 2012 | 147 | 0.090 |
Why?
| | Mutation | 1 | 2012 | 3964 | 0.090 |
Why?
| | Organ Transplantation | 2 | 2024 | 248 | 0.090 |
Why?
| | Male | 11 | 2024 | 67718 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2012 | 2066 | 0.090 |
Why?
| | Transfection | 2 | 2012 | 948 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2012 | 2838 | 0.080 |
Why?
| | Aorta, Thoracic | 2 | 2022 | 267 | 0.080 |
Why?
| | Mice | 2 | 2022 | 17843 | 0.070 |
Why?
| | Bone Morphogenetic Protein 2 | 2 | 2012 | 66 | 0.070 |
Why?
| | Female | 9 | 2024 | 73162 | 0.070 |
Why?
| | Alkaline Phosphatase | 2 | 2012 | 148 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5772 | 0.070 |
Why?
| | Patient Selection | 2 | 2012 | 691 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 442 | 0.070 |
Why?
| | Animals | 3 | 2022 | 37011 | 0.060 |
Why?
| | Databases, Factual | 2 | 2020 | 1351 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7593 | 0.060 |
Why?
| | Cell Survival | 2 | 2012 | 1122 | 0.060 |
Why?
| | Donor Selection | 1 | 2024 | 77 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2024 | 207 | 0.050 |
Why?
| | Shock | 1 | 2024 | 95 | 0.050 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 25 | 0.050 |
Why?
| | Cell Growth Processes | 1 | 2012 | 50 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 112 | 0.050 |
Why?
| | Surgical Mesh | 1 | 2012 | 49 | 0.050 |
Why?
| | Paraplegia | 1 | 2022 | 60 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 119 | 0.050 |
Why?
| | Airway Management | 1 | 2012 | 52 | 0.050 |
Why?
| | Workplace | 1 | 2024 | 261 | 0.050 |
Why?
| | Signal Transduction | 3 | 2013 | 5096 | 0.050 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 170 | 0.050 |
Why?
| | Blood Vessel Prosthesis | 1 | 2022 | 127 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 283 | 0.050 |
Why?
| | Tumor Burden | 1 | 2012 | 311 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 285 | 0.050 |
Why?
| | Occupational Health | 1 | 2024 | 208 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2012 | 233 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 270 | 0.040 |
Why?
| | Organ Size | 1 | 2012 | 479 | 0.040 |
Why?
| | Mice, Nude | 1 | 2012 | 696 | 0.040 |
Why?
| | Vascular Patency | 1 | 2020 | 105 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2022 | 242 | 0.040 |
Why?
| | Antitubercular Agents | 1 | 2012 | 206 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2012 | 4206 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 274 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 402 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 510 | 0.040 |
Why?
| | Down-Regulation | 1 | 2012 | 658 | 0.040 |
Why?
| | Syndrome | 1 | 2011 | 359 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 671 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 868 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 414 | 0.040 |
Why?
| | Anesthesia | 1 | 2012 | 191 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 282 | 0.040 |
Why?
| | Cattle | 1 | 2012 | 982 | 0.040 |
Why?
| | Postoperative Care | 1 | 2011 | 258 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 66 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2012 | 1324 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1703 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1377 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1018 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 489 | 0.040 |
Why?
| | Stents | 1 | 2022 | 528 | 0.040 |
Why?
| | Risk | 1 | 2020 | 905 | 0.030 |
Why?
| | Burnout, Professional | 1 | 2024 | 442 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 208 | 0.030 |
Why?
| | Biomarkers | 2 | 2012 | 4172 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1524 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2022 | 803 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1402 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1618 | 0.030 |
Why?
| | Lung Diseases | 1 | 2012 | 768 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2012 | 3546 | 0.030 |
Why?
| | Prognosis | 1 | 2012 | 4031 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2398 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3301 | 0.020 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2012 | 40 | 0.020 |
Why?
| | Osteopontin | 1 | 2012 | 34 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 1042 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2369 | 0.020 |
Why?
| | Pravastatin | 1 | 2011 | 41 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2011 | 66 | 0.020 |
Why?
| | Radiotherapy | 1 | 2012 | 201 | 0.020 |
Why?
| | Simvastatin | 1 | 2011 | 61 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 957 | 0.020 |
Why?
| | Hypertension | 1 | 2020 | 1293 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5730 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 437 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2681 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 211 | 0.020 |
Why?
| | Adolescent | 2 | 2023 | 21555 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 846 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1242 | 0.020 |
Why?
| | Infant | 1 | 2012 | 9467 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1185 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 646 | 0.020 |
Why?
| | Child, Preschool | 1 | 2012 | 11097 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 3205 | 0.010 |
Why?
| | Child | 1 | 2012 | 22037 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 13243 | 0.010 |
Why?
|
|
Rove's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|